Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study

被引：0
|
作者：
Modest, D. P. [1 ]
Tabernero, J. [2 ]
Prager, G. [3 ]
Fakih, M. [4 ]
Ciardiello, F. [5 ]
Van Cutsem, E. [6 ,7 ]
Elez, E. [2 ]
Cruz, F. [8 ]
Wyrwicz, L. [9 ]
Stroyakovskiy, D. [10 ]
Papai, Z. [11 ]
Poureau, P. -G. [12 ]
Liposits, G. [13 ]
Cremolini, C. [14 ]
Benhadji, K. [15 ]
Bondarenko, I. [16 ]
Skanji, D. [17 ]
Roby, L. [17 ]
Amellal, N. [17 ]
Taieb, J. [18 ]
机构：
[1] Charite, Hamatol Onkol & Tumorimmunol, Berlin, Germany
[2] Vall dHebron Univ Hosp & Inst Oncol VHIO, UVic UCC, IOB Quiron, Barcelona, Spain
[3] Med Univ Vienna, Dept Med 1, Vienna, Austria
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Campania Luigi Vanvitelli, Dept Precis Med, Neapel, Italy
[6] Univ Hosp Leuven, Dept Digest Oncol, Herent, Belgium
[7] Katholieke Univ Leuven, Dept Digest Oncol, Herent, Belgium
[8] Nucleo Pesquisa & Ensino Rede Sao Camilo, Sao Paulo, Brazil
[9] Maria Sklodowska Curie Natl Canc Res Inst, Dept Radiotherapy & Oncol, Warsaw, Poland
[10] Moscow City Oncol Hosp 62, Moscow, Russia
[11] Duna Med Ctr, Med Oncol, Budapest, Hungary
[12] Inst Cancerol, Brest, France
[13] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[14] Univ Pisa, Dept Translat Res & New Technol, Pisa, Italy
[15] Taiho Oncol Inc, Princeton, NJ USA
[16] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[17] Servier Int Res Inst, Suresnes, France
[18] Univ Paris Cite, Georges Pompidou European Hosp, SIRIC CARPEM, Paris, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V1019
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [21] Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial
    Prager, G.
    Taieb, J.
    Fakih, M.
    Ciardiello, F.
    Van Cutsem, E.
    Elez, E.
    Cruz, F.
    Wyrwicz, L.
    Stroyakovskiy, D.
    Papai, Z.
    Poureau, P.
    Liposits, G.
    Cremolini, C.
    Bondarenko, I.
    Modest, D.
    Amellal, N.
    Hassan, H.
    Skanji, D.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S184 - S184
  • [22] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Daisuke Kotani
    Yasutoshi Kuboki
    Satoshi Horasawa
    Asumi Kaneko
    Yoshiaki Nakamura
    Akihito Kawazoe
    Hideaki Bando
    Hiroya Taniguchi
    Kohei Shitara
    Takashi Kojima
    Akihito Tsuji
    Takayuki Yoshino
    [J]. BMC Cancer, 19
  • [23] Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer
    Masuishi, Toshiki
    Kuboki, Yasutoshi
    Terazawa, Tetsuji
    Nakamura, Masato
    Watanabe, Jun
    Ojima, Hitoshi
    Makiyama, Akitaka
    Kotaka, Masahito
    Hara, Hiroki
    Ohta, Takashi
    Oki, Eiji
    Sunakawa, Yu
    Ishihara, Soichiro
    Taniguchi, Hiroya
    Nakajima, Takako Eguchi
    Morita, Satoshi
    Shirao, Kuniaki
    Yoshino, Takayuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [24] Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil plus bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC).
    Pfeiffer, Per
    Yilmaz, Mette
    Moller, Soren
    Maltha, Line
    Krogh, Merete
    Zitnjak, Daniela
    Szameitat, Caroline Lemb
    Hejlesen, Finn
    Thomsen, Karina Gravgaard
    Qvortrup, Camilla
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
    Signorelli, Carlo
    Calegari, Maria Alessandra
    Basso, Michele
    Anghelone, Annunziato
    Lucchetti, Jessica
    Minelli, Alessandro
    Angotti, Lorenzo
    Zurlo, Ina Valeria
    Schirripa, Marta
    Chilelli, Mario Giovanni
    Morelli, Cristina
    Dell'Aquila, Emanuela
    Cosimati, Antonella
    Gemma, Donatello
    Ribelli, Marta
    Emiliani, Alessandra
    Corsi, Domenico Cristiano
    Arrivi, Giulia
    Mazzuca, Federica
    Zoratto, Federica
    Morandi, Maria Grazia
    Santamaria, Fiorenza
    Saltarelli, Rosa
    Ruggeri, Enzo Maria
    [J]. CURRENT ONCOLOGY, 2023, 30 (06) : 5456 - 5469
  • [26] Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
    Napolitano, Stefania
    De Falco, Vincenzo
    Martini, Giulia
    Esposito, Lucia
    Famiglietti, Vincenzo
    Martinelli, Erika
    Ciardiello, Davide
    Marrone, Francesca
    Avallone, Antonio
    Cardone, Claudia
    De Stefano, Alfonso
    Montesarchio, Vincenzo
    Zampino, M. Giulia
    Bordonaro, Roberto
    Scartozzi, Mario
    Santini, Daniele
    Di Maio, Massimo
    Ciardiello, Fortunato
    Troiani, Teresa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 129 - 129
  • [27] A phase II study of trifluridine/tipiracil, irinotecan, and bevacizumab in pretreated metastatic colorectal cancer (TABAsCO)
    Gupta, Medhavi
    Fountzilas, Christos
    Vijayvergia, Namrata
    Attwood, Kristopher
    Hochster, Howard S.
    Mukherjee, Sarbajit
    Iyer, Renuka V.
    Boland, Patrick Mckay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
    Taniguchi, Hiroya
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Kawakami, Takeshi
    Onozawa, Yusuke
    Honda, Kazunori
    Kadowaki, Shigenori
    Narita, Yukiya
    Tsushima, Takahiro
    Hamauchi, Satoshi
    Todaka, Akiko
    Yokota, Tomoya
    Ando, Masashi
    Mori, Keita
    Shirasu, Hiromichi
    Yasui, Hirofumi
    Muro, Kei
    [J]. ONCOLOGIST, 2023, : E1108 - E1113
  • [29] Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
    Taieb, Julien
    Prager, Gerald W.
    Fakih, Marwan
    Ciardello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe Melo
    Wyrwicz, Lucjan S.
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik Paul
    Roby, Lucas
    Barboux, Valentine
    Amellal, Nadia
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 111 - 111
  • [30] Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer
    Nakanishi, Koki
    Tanaka, Chie
    Kanda, Mitsuro
    Miyata, Kazushi
    Machida, Nozomu
    Sakai, Mitsuru
    Kobayashi, Daisuke
    Teramoto, Hitoshi
    Ishiyama, Akiharu
    Sato, Bin
    Oshima, Takashi
    Kajikawa, Masaki
    Matsushita, Hidenobu
    Ishigure, Kiyoshi
    Yamashita, Katsuya
    Fujitake, Shinichi
    Sueoka, Satoshi
    Asada, Takahiro
    Shimizu, Dai
    Sugita, Shizuki
    Kuwatsuka, Yachiyo
    Maeda, Osamu
    Furune, Satoshi
    Murotani, Kenta
    Ando, Yuichi
    Ebata, Tomoki
    Kodera, Yasuhiro
    [J]. NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (01): : 43 - 51
12345